Correlation between PET-CT and ct in the staging after the treatment of head and neck squamous cell carcinoma.

Autor: García-Curdi F; Hospital Santa Bárbara, Department of Otorhinolaryngology, Soria, Spain. Electronic address: fgcurdi@gmail.com., Lois-Ortega Y; Hospital Santa Bárbara, Department of Otorhinolaryngology, Soria, Spain., Muniesa-Del Campo A; Universidad de Zaragoza, Faculty of Veterinary Sciences, Department of Animal Pathology, Zaragoza, Spain., McGee-Laso A; Hospital Ramon y Cajal, Department of Preventive Medicine and Public Health, Madrid, Spain., Sebastián-Cortés JM; Hospital Clínico Universitario Lozano Blesa, Department of Otorhinolaryngology, Zaragoza, Spain., Vallés-Varela H; Hospital Clínico Universitario Lozano Blesa, Department of Otorhinolaryngology, Zaragoza, Spain., Lambea-Sorrosal JJ; Hospital Clínico Universitario Lozano Blesa, Department of Otorhinolaryngology, Zaragoza, Spain.

Publikováno v: Brazilian journal of otorhinolaryngology [Braz J Otorhinolaryngol] 2022 Nov-Dec; Vol. 88 Suppl 4, pp. S143-S151. Date of Electronic Publication: 2021 Dec 07.

Differences in survival according to malignancy type and degree of immunodeficiency in HIV-infected patients.

Autor: Fernández-Ruiz A; Servicio de Oncología Médica, Hospital General San Jorge, Huesca, España. Electronic address: afdezru@gmail.com., Sanjoaquín-Conde I; Servicio de Enfermedades Infecciosas, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España., Letona-Carbajo S; Servicio de Enfermedades Infecciosas, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España., Lambea-Sorrosal JJ; Servicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España., Crusells-Canales MJ; Servicio de Enfermedades Infecciosas, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.

Publikováno v: Medicina clinica [Med Clin (Barc)] 2020 Apr 24; Vol. 154 (8), pp. 295-300. Date of Electronic Publication: 2019 Aug 27.

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.

Autor: Pérez-Valderrama B; Department of Medical Oncology, Virgen del Rocío University Hospitals, Sevilla bperezv@gmail.com., Arranz Arija JA; Department of Medical Oncology, Gregorio Marañón General University Hospital, Madrid., Rodríguez Sánchez A; Department of Medical Oncology, University Hospital of León, Leon., Pinto Marín A; Department of Medical Oncology, La Paz University Hospital, Madrid., Borrega García P; Department of Medical Oncology, San Pedro de Alcántara Hospital, Cáceres., Castellano Gaunas DE; Department of Medical Oncology, 12 de Octubre University Hospital, Madrid., Rubio Romero G; Department of Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid., Maximiano Alonso C; Department of Medical Oncology, Puerta de Hierro University Hospital, Majadahonda (Madrid)., Villa Guzmán JC; Department of Medical Oncology, General University Hospital of Ciudad Real, Ciudad Real., Puertas Álvarez JL; Department of Medical Oncology, Rio Hortega University Hospital, Valladolid., Chirivella González I; Department of Medical Oncology, University Hospital of Valencia, Valencia., Méndez Vidal MJ; Department of Medical Oncology, Reina Sofía University Hospital, Córdoba., Juan Fita MJ; Department of Medical Oncology, Valencian Institute of Oncology, Valencia., León-Mateos L; Department of Medical Oncology, Santiago University Hospital Complex, Santiago de Compostela., Lázaro Quintela M; Department of Medical Oncology, University Hospital Complex of Vigo, Vigo., García Domínguez R; Department of Medical Oncology, Clinic University Hospital of Salamanca, Salamanca., Jurado García JM; Department of Medical Oncology, San Cecilio University Hospital, Granada., Vélez de Mendizábal E; Department of Medical Oncology, San Pedro Hospital, Logroño., Lambea Sorrosal JJ; Department of Medical Oncology, Lozano Blesa University Hospital, Zaragoza., García Carbonero I; Department of Medical Oncology, Virgen de la Salud Hospital, Toledo., González del Alba A; Department of Medical Oncology, Son Espases University Hospital, Palma de Mallorca., Suárez Rodríguez C; Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona., Jiménez Gallego P; Department of Medical Oncology, Doctor Negrín University Hospital of Gran Canaria, Las Palmas de Gran Canaria., Meana García JA; Department of Medical Oncology, University Hospital of Alicante, Alicante., García Marrero RD; Department of Medical Oncology, University Hospital of Canarias, San Cristóbal de La Laguna (Santa Cruz de Tenerife)., Gajate Borau P; Department of Medical Oncology, Quirón University Hospital, Madrid., Santander Lobera C; Department of Medical Oncology, Miguel Servet University Hospital, Zaragoza., Molins Palau C; Department of Medical Oncology, Doctor Peset University Hospital, Valencia., López Brea M; Department of Medical Oncology, Marqués de Valdecilla University Hospital, Santander., Fernández Parra EM; Department of Medical Oncology, Nuestra Señora de Valme University Hospital, Sevilla., Reig Torras O; Department of Medical Oncology, Clinic University Hospital of Barcelona, Barcelona., Basterretxea Badiola L; Department of Medical Oncology, Donostia University Hospital, San Sebastián., Vázquez Estévez S; Department of Medical Oncology, Lucus Augusti University Hospital, Lugo., González Larriba JL; Department of Medical Oncology, San Carlos University Hospital, Madrid, Spain.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2016 Apr; Vol. 27 (4), pp. 706-11. Date of Electronic Publication: 2015 Dec 09.